Overview

XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Epidemiological and Clinical Research Information Network
Treatments:
Capecitabine
Cisplatin